Quantum-Si Incorporated Stock Price, News & Analysis

Quantum-Si and ESPCI Paris researchers have developed a groundbreaking method for measuring single-molecule binding kinetics at scale using QSI's Platinum Next-Gen Protein Sequencing instrument. The technique combines protein barcode sequencing with real-time single-molecule interaction data, enabling parallel analysis of protein variants without genotype-phenotype coupling. The method was validated across 20 nanobody variants showing strong correlation with SPR, demonstrating a 1,000-fold range in affinity. The platform allows for high-throughput measurement of tens of thousands of single molecules per run and has potential to scale to over 1,000-member barcode sets. This innovation makes single-molecule analysis more accessible and practical for applications in drug discovery, protein engineering, and disease biology research.

Quantum-Si (Nasdaq: QSI) reported its Q1 2025 financial results, highlighting revenue of $842,000, an 84% increase from Q1 2024. The company successfully launched and delivered its first Platinum® Pro units and expanded its international channel network to 23 partners. Key developments include the on-track progress of Proteus™ Platform, v4 Sequencing Kit (expected Q3 2025), and a new v3 Library Preparation Kit (expected end of 2025). Financial metrics show a gross profit of $486,000 with 58% margin, and operating expenses of $25.6M. The company reported a net loss of $19.2M. Following a $50M registered direct offering in January 2025, QSI holds $232.6M in cash and investments, providing runway into second half of 2027. The company noted challenges in the U.S. market due to NIH funding and tariff uncertainty but remains optimistic about opportunities in pharma, biotech, and international markets.

Quantum-Si (NASDAQ: QSI) has announced the granting of 16,555 restricted stock units (RSUs) to new employees as part of its 2023 Inducement Equity Incentive Plan. The RSUs were granted as inducement awards under Nasdaq Listing Rule 5635(c)(4), specifically designed for new hires who were not previously employed by the company. The vesting schedule includes 25% vesting on June 20, 2026, followed by the remaining amount vesting in 12 equal quarterly installments. The grants are contingent upon continued employment with Quantum-Si through the vesting dates.

Quantum-Si (Nasdaq: QSI) announces an upcoming Nature webinar featuring Dr. Gloria Sheynkman from the University of Virginia on May 15, 2025. The presentation, titled "Precision Proteomics: Next-Gen Protein Sequencing for Proteoform Detection and Characterization," will showcase research utilizing QSI's Platinum® Next-Gen Protein Sequencing™ (NGPS™) platform.

Dr. Sheynkman will present findings from her team's study on tropomyosin proteoforms, demonstrating the platform's capability to detect protein variations at the single-molecule level. The webinar, scheduled for 8:00 a.m. PDT / 11:00 a.m. EDT, highlights QSI's innovative technology that enables single-amino acid resolution and high-specificity detection of endogenous proteins.

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company, has scheduled its first quarter 2025 financial results announcement for Thursday, May 15, 2025. The company will host a conference call and webcast at 4:30 PM ET on the same day, featuring President and CEO Jeff Hawkins and CFO Jeff Keyes, who will discuss the financial performance and provide a business update.

Interested participants can join via live webcast through the Investors section of Quantum-Si's website under Events and Presentations, or register for a personalized dial-in number to join the call. A replay of the webcast will be available after the event.

Quantum-Si (Nasdaq: QSI) has begun shipping its latest benchtop protein sequencer, Platinum® Pro, designed to make Next-Gen Protein Sequencing™ more accessible globally. The new system builds upon the original Platinum model with enhanced features including:

• An enlarged touchscreen with intuitive user interface
• Flexible local or cloud-based data analysis options
• Pro Mode for custom application development through a Technology Access Program

The system offers single-molecule precision protein analysis through an integrated workflow and is now available in over 30 countries through direct and channel partner networks. According to CEO Jeff Hawkins, Platinum Pro aims to advance proteomics research and enable new biomarker discoveries.

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.

Featured speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:

• The growing impact of proteomics in multi-omics analysis
• Applications for cancer and other disease research
• Technologies and strategies for large-scale discovery and data analysis
• Tools for orthogonal validation of proteins of interest

Quantum-Si (Nasdaq: QSI), The Protein Sequencing Company™, has announced its participation in an upcoming DNAnexus webinar focused on proteomics in multi-omics research. The virtual event, scheduled for March 25, 2025, at 8 a.m. PT/11 a.m. ET, will explore how integrating proteomics data with other omics datasets drives new discoveries in disease research, including cancer.

Key speakers include Meredith Carpenter, PhD from Quantum-Si, Cindy Lawley, PhD from Olink, Thermo Fisher Scientific, and Theresa Wohlever from DNAnexus. The webinar will cover:

• The growing impact of proteomics in multi-omics analysis
• Applications for cancer and other disease research
• Technologies and strategies for large-scale discovery and data analysis
• Tools for orthogonal validation of proteins of interest

Quantum-Si (Nasdaq: QSI) has announced new employee inducement grants approved by its Board's Compensation Committee. The company granted 20,833 restricted stock units (RSUs) to new employees under its 2023 Inducement Equity Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).

The RSUs vesting schedule includes 25% vesting on March 20, 2026, with the remaining portion vesting in 12 equal quarterly installments thereafter. Vesting is contingent upon continued employment with Quantum-Si. These equity awards are specifically designed for new hires who were not previously employed by the company, serving as an inducement for joining Quantum-Si.